drugset / Trial / NCT02366845

Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease

NCT02366845

Phase 4 Completed 50 enrolled University of Colorado, Denver
RandomizedParallel-groupSingle-blindTreatment

Summary

This study plans to learn more about transfusion of a human blood component called plasma in patients who have liver problems. Patients are asked to be in this study because they have liver disease and therefore may require the transfusion of plasma. The dose of plasma required to reach certain blood clotting laboratory targets is usually determined by clinicians. Due to the complexity of the patient's blood clotting disorder, determining the appropriate dose of plasma is very difficult. The investigators have developed a dosing table based on information from other patients with liver disease and the investigators are testing it to see if it is a more accurate dosing tool then clinician chosen dosing of plasma in patients with liver disease who need one or more plasma transfusions

Timeline

Start
2012-06-27
Primary completion
2015-06-24
Completion
2019-03-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fresh Frozen Plasma Protein / enzyme biologic Other

Indications